Argen X SE

ARGX
366,10
-2,10 (-0,57%)
28 Mar 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: Euronext
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
27/3/202407:00GLOBEargenx Advances Clinical Development of Efgartigimod in..
26/3/202421:00GLOBEargenx Announces Annual General Meeting of Shareholders on..
26/3/202407:00GLOBEargenx Announces Approval of VYVGART (efgartigimod alfa) in..
07/3/202422:01GLOBEargenx Delivers on Promise to Transform Patient Expectations..
29/2/202407:00GLOBEargenx Reports Full Year 2023 Financial Results and Provides..
26/2/202407:00GLOBEargenx to Present at Upcoming Investor Conferences
22/2/202407:00GLOBEargenx to Report Full Year 2023 Financial Results and Fourth..
20/2/202407:00GLOBEargenx Announces FDA Acceptance of Supplemental Biologics..
18/1/202407:00GLOBEargenx Announces Approval of VYVDURA® (efgartigimod alfa and..
08/1/202407:00GLOBEargenx Highlights 2024 Strategic Priorities
02/1/202407:00GLOBEargenx to Present at 42nd Annual J.P. Morgan Healthcare..
20/12/202307:00GLOBEargenx Reports Topline Results from ADDRESS Study of..
28/11/202307:00GLOBEargenx Reports Topline Results from ADVANCE-SC Study of..
16/11/202313:40GLOBEargenx Announces European Commission Approval of..
01/11/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
31/10/202307:00GLOBEargenx Reports Third Quarter 2023 Financial Results and..
24/10/202307:00GLOBEargenx to Report Third Quarter 2023 Financial Results and..
21/9/202307:00GLOBEargenx Announces VYVGART (efgartigimod alfa) Authorized for..
15/9/202307:00GLOBEargenx Announces Positive CHMP Opinion for Subcutaneous..
30/8/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
27/7/202307:00GLOBEargenx Reports Half Year 2023 Financial Results and Provides..
24/7/202322:30GLOBEargenx announces closing of global offering
20/7/202307:00GLOBEargenx to Report Half Year 2023 Financial Results and Second..
19/7/202323:58GLOBEargenx announces full exercise of underwriters’ option to..
19/7/202303:30GLOBEargenx raises $1.1 billion in gross proceeds in a global..
17/7/202322:01GLOBEargenx announces launch of proposed global offering
17/7/202307:00GLOBEargenx Reports Positive Topline Data from ADHERE Study of..
30/6/202315:39GLOBEargenx and Zai Lab Announce Approval of VYVGART®..
21/6/202300:12GLOBEargenx Announces U.S. Food and Drug Administration Approval..
20/6/202307:00GLOBEargenx Initiates Second Cohort of Phase 2 ARDA Study of..
31/5/202307:00GLOBEargenx to Present at Upcoming Investor Conferences
04/5/202307:00GLOBEargenx Reports First Quarter 2023 Financial Results and..
03/5/202322:01GLOBEargenx announces results of Annual General Meeting of..
02/5/202307:00GLOBEargenx to Present at BofA Securities 2023 Health Care..
27/4/202307:00GLOBEargenx to Report First Quarter 2023 Financial Results and..
18/4/202307:00GLOBEargenx Demonstrates Commitment to Redefining Treatment Goals..
17/4/202308:00GLOBEargenx and Genmab Enter Partnership to Advance Antibody..
Apertura: 368,20 Min: 364,60 Max: 371,80
Chiusura: 368,20

La tua Cronologia

Delayed Upgrade Clock

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network